-- Earnings Flash (OTIC) OTONOMY Reports Q1 Loss $-0.20, vs. Street Est of $-0.20
4:24PM ET 5/09/2022 MT Newswires...
Quotes Snapshot > OTIC
Otonomy Inc OTIC:NASDAQ
Last Price$2.02Cboe Previous Close - Real-Time Last Sale as of 4:01PM ET 6/24/22
Cboe Real-Time Quotes
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$1.98 (1,000)
Ask (Size)$2.38 (2)
Day Low / HighN/A - N/A
Volume762.1 K
Read more news Recent News
--Oppenheimer Adjusts Otonomy Price Target to $6 From $5, Maintains Outperform Rating
12:51PM ET 4/21/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Otonomy Says Hearing Loss Treatment Drug Showed Clinical Benefit During Phase 2a Trial
7:57AM ET 4/20/2022 MT NewswiresOtonomy (OTIC) said Wednesday that its OTO-413 drug showed clinically meaningful treatment benefit in patients with hearing loss during a phase 2a trial. ...
-- Earnings Flash (OTIC) OTONOMY Posts Q4 Loss $-0.20, vs. Street Est of $-0.18
4:28PM ET 2/28/2022 MT Newswires...
View all Commentary and Analysis
Otonomy, Inc. 2022 Q1 - Results - Earnings Call Presentation
1:05PM ET 5/16/2022 Seeking AlphaOtonomy, Inc. (OTIC) CEO Dr. David Weber on Q1 2022 Results - Earnings Call Transcript
10:21PM ET 5/09/2022 Seeking AlphaOtonomy: Hearing Loss And Tinnitus Data In 2022
12:23PM ET 4/04/2022 Seeking AlphaTracking Baker Brothers Portfolio - Q4 2021 Update
10:10PM ET 3/30/2022 Seeking AlphaCompany Profile
Business DescriptionOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. View company web site for more details
| Address | 4796 Executive Drive San Diego, California 92121 |
| Phone | +1.619.323.2200 |
| Number of Employees | 49 |
| Recent SEC Filing | 06/23/2022 4 |
| President, Chief Executive Officer & Director | David A. Weber |
| Vice President -Technical operations | Anna Stepannenko |
| Chief Financial & Business Officer | Paul E. Cayer |
| Vice President-Research & Preclinical Development | Fabrice Piu |
Company Highlights
| Price Open | $1.96 |
| Previous Close | $2.02 |
| 52 Week Range | $1.14 - 2.59 |
| Market Capitalization | $115.0 M |
| Shares Outstanding | 56.9 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/03/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.78 |
| Beta vs. S&P 500 | N/A |
| Revenue | $745.0 K |
| Net Profit Margin | -150,065.71% |
| Return on Equity | -86.69% |
Analyst Ratings as of 11/11/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |